<DOC>
	<DOC>NCT02521376</DOC>
	<brief_summary>The primary objective of this study is to evaluate the pharmacokinetics of Entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate) relative to matched, healthy controls.</brief_summary>
	<brief_title>Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function</brief_title>
	<detailed_description />
	<criteria>Calculated body mass index from 18 to 40 kg/m^2 Not pregnant Normal electrocardiogram Participants with impaired liver function must be sufficiently healthy based upon medical history and physical examination, vital signs, and screening laboratory evaluations. Participation in another clinical study (current or within last 30 days) HIV, hepatitis B virus, or active hepatitis C virus infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>